Sarepta Therapeutics (STU:AB3A) Current Accrued Expense : €125 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sarepta Therapeutics Current Accrued Expense?

Sarepta Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was €125 Mil.

Sarepta Therapeutics's quarterly Current Accrued Expense declined from Sep. 2023 (€151 Mil) to Dec. 2023 (€112 Mil) but then increased from Dec. 2023 (€112 Mil) to Mar. 2024 (€125 Mil).

Sarepta Therapeutics's annual Current Accrued Expense increased from Dec. 2021 (€143 Mil) to Dec. 2022 (€257 Mil) but then declined from Dec. 2022 (€257 Mil) to Dec. 2023 (€112 Mil).

Sarepta Therapeutics Current Accrued Expense Historical Data

The historical data trend for Sarepta Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Current Accrued Expense Chart

Sarepta Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

87.33

82.31

142.52

256.53

112.26

Sarepta Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															217.55	166.82	150.72	112.26	124.84

Sarepta Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Sarepta Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (STU:AB3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (STU:AB3A) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

SRPT:USA S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (STU:AB3A) Headlines

No Headlines